ImmuNext
Founded 2011
About ImmuNext
ImmuNext develops compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Novel immunomodulators have been partnered with Janssen, Roche and Sanofi. ImmuNext currently has a clinical stage program with VISTA, a checkpoint regulator, and pre-clinical programs focused on the development of antibodies that target novel immuno-metabolic proteins.
Company Facts
- Founded: 2011
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Website: http://immunext.com/
- Phone: [email protected]
Social Profiles
Canonical: https://fsome.com/organization/immunext-8457080 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.